Reporting Date | Major Shareholder Name | Shares Held | Market Value | Change in Shares | Ownership |
---|---|---|---|---|---|
05/15/2024 | HUDSON BAY CAPITAL MANAGEMENT LP | 86,753 | $36,436 | 0.00% | 0.56% |
05/13/2024 | CLEAR STREET LLC | 59,172 | $25,000 | -0.17% | 0.38% |
05/15/2024 | CITADEL ADVISORS LLC | 48,138 | $20,218 | 100.00% | 0.31% |
05/06/2024 | WARBERG ASSET MANAGEMENT LLC | 41,406 | $17,391 | -34.80% | 0.27% |
A. During the previous two years, 5 institutional investors and hedge funds held shares of NeuroSense Therapeutics Ltd.. The most heavily invested institutionals were:
Hudson Bay Capital Management LP: 86,753
CLEAR STREET LLC: 59,172
CITADEL ADVISORS LLC: 48,138
Warberg Asset Management LLC: 41,406
Empery Asset Management, LP: 160,000
A. 1.53% of NeuroSense Therapeutics Ltd. stock is owned by institutional investors.
A. Institutional investors have bought a total of 395,469 shares in the last 24 months. This purchase volume represents approximately $94,913 in transactions.